Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients von Hochmair, M.J., Weinlinger, C., Fabikan, H., Koger, R., Krenbeck, D., Huemer, F., Illini, O.M., Kulaksiz, M., Valipour, A., Burghuber, O.C.

Volltext

63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients von Hochmair, M J, Weinlinger, C, Fabikan, H, Koger, R, Krenbeck, D, Huemer, F, Illini, O M, Kulaksiz, M, Valipour, A, Burghuber, O C

Volltext

EP02.01-008 Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas von Zacharias, M., Konjic, S., Absenger, G., Hochmair, M.J., Fabikan, H., Weinlinger, C., Illini, O., Jost, P.J., Schlintl, V., Wurm, R., Lindenmann, J., Fediuk, M., Brcic, L., Terbuch, A.

Volltext

EP08.02-122 Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP) von Illini, O., Fabikan, H., Swalduz, A., Krenbek, D., Vikström, A., Schumacher, M., Dudnik, E., Studnicka, M., Öhman, R., Wurm, R., Wannesson, L., Peled, N., Kian, W., Bar, J., Daher, S., Addeo, A., Rotem, O., Pall, G., Zer, A., Saad, A., Cufer, T., Sorotsky, H.G., Hashemi, S.M.S., Mohorcic, K., Stoff, R., Rovitsky, Y., Keren-Rosenberg, S., Winder, T., Weinlinger, C., Valipour, A., Hochmair, M.J.

Volltext

P2.14-46 Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROS1 Rearranged NSCLC Patients von Hochmair, M.J., Weinlinger, C., Fabikan, H., Illini, O., Krenbek, D., Setinek, U., Watzka, S., Koger, R., Meilinger, M., Absenger, G., Wanke, M., Semmelweis, C., Rauter, M., Valipour, A.

Volltext